QuidelOrtho Corp (QDEL): Free Cash Flow
-$83.00M
Year ended 2025-12-28
-$211.20M
Trailing 12 months to 2026-06-28
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-28 | -$83.00M | n/m | 2026-02-19, From 2024-12-30 |
| 2024-12-29 | -$112.10M | n/m | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | $70.90M | -90.5% | 2026-02-19, From 2023-01-02 |
| 2023-01-01, Fiscal 2022 | $744.40M | +45.1% | 2025-02-27, From 2022-01-03 |
| 2022-01-02, Fiscal 2021 | $513.10M | -9.2% | 2024-08-01, From 2021-01-04 |
| 2021-01-03, Fiscal 2020 | $564.80M | n/a | 2023-02-23, From 2019-12-30 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | 2025-12-28 | -$83.00M | n/m |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $1.06B | +30.8% |
| Neogen Corp (NEOG) | 2026-05-31 | $31.90M | n/m |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | -$395.87M | n/m |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | -$9.79M | n/m |
| Immucell Corp (ICCC) | 2025-12-31 | $1.22M | n/m |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | -$7.04M | n/m |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | -$25.37M | n/m |
| Volitionrx Ltd (VNRX) | 2025-12-31 | -$19.77M | n/m |
Compare QDEL, IDXX, NEOG, NTLA side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗